Neurocrine Biosciences (NBIX) Change in Acquisitions & Divestments (2010 - 2026)

Neurocrine Biosciences has reported Change in Acquisitions & Divestments for 17 years, with the latest figure at $2.3 billion in Q2 2026.

• Change in Acquisitions & Divestments for Q2 2026 came in at $2.3 billion, up 659.65% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.0 billion (up 171.41% YoY), and the FY2025 annual result was $1.1 billion, up 12.6% from the prior year.
• Change in Acquisitions & Divestments improved to $2.3 billion in Q2 2026, from $259.2 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $2.3 billion in Q2 2026 and troughed at $71.2 million in Q3 2022.
• A 5-year average of $337.1 million and a median of $255.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The widest annual swing landed in 2022, when Change in Acquisitions & Divestments slumped 55.42%; it then jumped 659.65% in 2026.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $162.2 million in 2022, then jumped by 79.28% to $290.8 million in 2023, then slipped by 13.76% to $250.8 million in 2024, then increased by 6.74% to $267.7 million in 2025, then surged by 747.33% to $2.3 billion in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $2.3 billion in Q2 2026, $259.2 million in Q1 2026, and $267.7 million in Q4 2025.